Translational success stories: Development of direct thrombin inhibitors

Circulation Research

Volumn 111, Issue 7, 2012, Pages 920-929

  Coppens, Michiel ^a,b,e   Eikelboom, John W ^a,b,c   Gustafsson, David ^d   Weitz, Jeffrey I ^b,c   Hirsh, Jack ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d ASTRAZENECA R AND D   (Sweden)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

anticoagulant; drug development; thrombin

Indexed keywords

ARGATROBAN; DABIGATRAN ETEXILATE; DESULFATOHIRUDIN; FIBRINOPEPTIDE A; HEPARIN; HIRULOG; LEPIRUDIN; RECOMBINANT HIRUDIN; THROMBIN; THROMBIN INHIBITOR; XIMELAGATRAN;

CLINICAL TRIAL; CRYSTAL STRUCTURE; DRUG ADSORPTION; DRUG STRUCTURE; HUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS; VEIN THROMBOSIS;

ANTICOAGULANTS; ANTITHROMBINS; HIRUDIN THERAPY; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; RECOMBINANT PROTEINS; THROMBOSIS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84866552305     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.112.264903     Document Type: Review

References (83)

1. Haycraft JB. Ü ber die Einwirkung eines Sekretes des officinellen Blutegels auf die Gerinnbarkeit des Bluts. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1894;18:209-217.
2. Bergmann C, Dodt J, Kohler S, Fink E, Gassen HG. Chemical synthesis and expression of a gene coding for hirudin, the thrombin-specific inhibitor from the leech Hirudo medicinalis. Biol Chem Hoppe Seyler. 1986; 367:731-740.
3. Franz F. Ü ber den die Blutgerinnung aufhebenden Bestandteil des medizinischen Blutegels. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1903;49:342-357.
4. Harvey RP, Degryse E, Stefani L, Schamber F, Cazenave JP, Courtney M, Tolstoshev P, Lecocq JP. Cloning and expression of a cDNA coding for the anticoagulant hirudin from the bloodsucking leech, Hirudo medicinalis. Proc Natl Acad Sci U S A. 1986;83:1084-1088.
5. Markwardt F. [Studies on the mechanism of the anticoagulant effect of hirudin]. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1956;229:389-399.
6. Bettelheim FR. The clotting of fibrinogen II: fractionation of peptide material liberated. Biochim Biophys Acta. 1956;19:121-130.
7. Bode W, Mayr I, Baumann U, Huber R, Stone SR, Hofsteenge J. The refined 1.9 A crystal structure of human alpha-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J. 1989;8:3467-3475.
8. Rydel TJ, Ravichandran KG, Tulinsky A, Bode W, Huber R, Roitsch C, Fenton JW. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science. 1990;249:277-280.
9. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385-391.
10. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012; 11:191-200.
11. Morawitz PO. Die Chemie der Blutgerinnung. Ergeb Physiol. 1905;4:307-422.
12. Crawley JT, Zanardelli S, Chion CK, Lane DA. The central role of thrombin in hemostasis. J Thromb Haemost. 2007;5(Suppl 1):95-101.
13. Blombäck B, Blombäck M, Gröndahl NJ, Holmberg E. Structure of fibrinopeptides, its relation to enzyme specificity and phylogeny and classification of species. Ark Kemi. 1966;25:411-416.
14. Blombäck B, Blombäck M, Olsson P, Svendsen L, Aberg G. Synthetic peptides with anticoagulant and vasodilating activity. Scand J Clin Lab Invest Suppl. 1969;107:59-61.
15. Marsh HC Jr, Meinwald YC, Lee S, Scheraga HA. Mechanism of action of thrombin on fibrinogen: direct evidence for the involvement of phe-nylalanine at position P9. Biochemistry. 1982;21:6167-6171.
16. Bajusz S, Barabas E, Tolnay P, Szell E, Bagdy D. Inhibition of thrombin and trypsin by tripeptide aldehydes. Int J Pept Protein Res. 1978;12:217-221.
17. Kettner C, Shaw E. D-Phe-Pro-ArgCH2Cl-A selective affinity label for thrombin. Thromb Res. 1979;14:969-973.
18. Markwardt F, Wagner G, Sturzebecher J, Walsmann P. N alpha-arylsulfonyl- omega-(4-amidinophenyl)-alpha-aminoalkylcarboxylic acid amides: novel selective inhibitors of thrombin. Thromb Res. 1980;17:425-431.
19. Petersen TE, Roberts HR, Sotrup-Jensen L, Magnusson S. Primary structure of hirudin, a thrombin-specific inhibitor. In: Peeters H, ed. Protides of the Biologic Fluids. Oxford: Pergamon Press; 1976:145-149.
20. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res. 1994;74:1-23.
21. Eriksson BI, Wille-Jorgensen P, Kalebo P, Mouret P, Rosencher N, Bosch P, Baur M, Ekman S, Bach D, Lindbratt S, Close P. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med. 1997;337:1329-1335.
22. Schiele F, Lindgaerde F, Eriksson H, Bassand JP, Wallmark A, Hansson PO, Grollier G, Sjo M, Moia M, Camez A, Smyth V, Walker M. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. International Multicentre Hirudin Study Group. Thromb Haemost. 1997;77:834-838.
23. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascu-larisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet. 1999;353:429-438.
24. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996;335:775-782.
25. Serruys PW, Herrman JP, Simon R, Rutsch W, Bode C, Laarman GJ, van DR, van den Bos AA, Umans VA, Fox KA, A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty: Helvetica Investigators N Engl J Med. 1995;333:757-763.
26. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation. 1996;94:911-921.
27. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood. 2000;96:846-851.
28. Lubenow N, Eichler P, Lietz T, Greinacher A. Lepirudin in patients with heparin-induced thrombocytopenia-results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3 J. Thromb Haemost. 2005;3:2428-2436.
29. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e24S-e43S.
30. Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced throm-bocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thromb Haemost. 2011;9:2389-2396.
31. Lobo B, Finch C, Howard A, Minhas S. Fondaparinux for the treatment of patients with acute heparin-induced thrombocytopenia. Thromb Haemost. 2008;99:208-214.
32. Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem. 1989; 264:8692-8698.
33. Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood. 1990;75:399-406.
34. Stone SR, Braun PJ, Hofsteenge J. Identification of regions of alpha-thrombin involved in its interaction with hirudin. Biochemistry. 1987;26:4617-4624.
35. Skrzypczak-Jankun E, Carperos VE, Ravichandran KG, Tulinsky A, Westbrook M, Maraganore JM. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J Mol Biol. 1991;221:1379-1393.
36. Maraganore JM, Bourdon P, Jablonski J, Ramachandran KL, Fenton JW. Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry. 1990;29:7095-7101.
37. Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned gly-coprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003;289:853-863.
38. Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006;355:2203-2216.
39. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008;358:2218-2230.
40. Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Fahy M, Parise H, Mehran R. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet. 2011;377:2193-2204.
41. Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL, Kirshner R, Lincoff AM, Spiess BD. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopul-monary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg. 2006;131:533-539.
42. Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T, McCarthy HL, Lincoff AM, Spiess BD, Aronson S. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg. 2006;131:686-692.
43. Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Sicurella J, Brill-Edwards P, Levine MN, Panju AA, Powers P, Stevens P, Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery Circulation. 1994;90:2385-2389.
44. Ginsberg JS, Nurmohamed MT, Gent M, MacKinnon B, Stevens P, Weitz J, Maraganore J, Hirsh J. Effects on thrombin generation of single injections of Hirulog in patients with calf vein thrombosis. Thromb Haemost. 1994;72:523-525.
45. Dyke CM, Aldea G, Koster A, Smedira N, Avery E, Aronson S, Spiess BD, Lincoff AM. Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg. 2007;84:836-839.
46. Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL, Aronson S, Hetzer R, Avery E, Spiess B, Lincoff AM. Bivalirudin during cardiopul-monary bypass in patients with previous or acute heparin-induced throm-bocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg. 2007;83:572-577.
47. Mahaffey KW, Lewis BE, Wildermann NM, Berkowitz SD, Oliverio RM, Turco MA, Shalev Y, Ver LP, Traverse JH, Rodriguez AR, Ohman EM, Harrington RA, Califf RM. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol. 2003;15:611-616.
48. Okamoto S, Hijikata A, Kinjo K, Kikumoto R, Okubo K. A novel series of synthetic thrombin-inhibitors having extremely potent and highly selective action. Kobe J Med Sci. 1975;21:43-51.
49. Okamoto S, Hijikata A, Kikumoto R, Tonomura S, Hara H, Ninomiya K, Maruyama A, Sugano M, Tamao Y. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805: the importance of stereo-structure of its hydrophobic carboxamide portion. Biochem Biophys Res Commun. 1981;101:440-446.
50. Banner DW, Hadvary P. Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors. J Biol Chem. 1991;266:20085-20093.
51. Lewis BE, Wallis DE, Berkowitz SD, Matthai WH, Fareed J, Walenga JM, Bartholomew J, Sham R, Lerner RG, Zeigler ZR, Rustagi PK, Jang IK, Rifkin SD, Moran J, Hursting MJ, Kelton JG. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation. 2001;103:1838-1843.
52. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med. 2003;163:1849-1856.
53. Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E. Effect of Thrombin Inhibition on Patients with Peripheral Arterial Obstructive Disease: a Multicenter Clinical Trial of Argatroban. J Thromb Throm-bolysis. 1995;2:131-136.
54. Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost. 1997;23:531-534.
55. Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol. 1993;21:1039-1047.
56. Herrman JP, Suryapranata H, den HP, Gabriel L, Kutryk MJ, Serruys PW. Argatroban During Percutaneous Transluminal Coronary Angioplasty: results of a dose-verification study. J Thromb Thrombolysis. 1996;3:367-375.
57. Vermeer F, Vahanian A, Fels PW, Besse P, Muller E, Van de Werf F, Fitzgerald D, Darius H, Puel J, Garrigou D, Simoons ML. Argatroban and alteplase in patients with acute myocardial infarction: the ARGAMI Study. J Thromb Thrombolysis. 2000;10:233-240.
58. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 1997;23:3-25.
59. Gustafsson D, Bylund R, Antonsson T, Nilsson I, Nystrom JE, Eriksson U, Bredberg U, Teger-Nilsson AC. A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Discov. 2004;3:649-659.
60. Gustafsson D. Discovery of ximelagatran in an historical perspective. Semin Vasc Med. 2005;5:227-234.
61. Gustafsson D, Antonsson T, Bylund R, Eriksson U, Gyzander E, Nilsson I, Elg M, Mattsson C, Deinum J, Pehrsson S, Karlsson O, Nilsson A, Sorensen H. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost. 1998; 79:110-118.
62. Muller TH, Weisenberger H, Brickl R, Narjes H, Himmelsbach F, Krause J. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 1997;96:1130-1138.
63. Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, Bylund R. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res. 2001;101:171-181.
64. Eriksson BI, Bergqvist D, Kalebo P, Dahl OE, Lindbratt S, Bylock A, Frison L, Eriksson UG, Welin L, Gustafsson D. Ximelagatran and mela-gatran compared with dalteparin for prevention of venous thromboem-bolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 2002;360:1441-1447.
65. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Lassen MR, Mouret P, Rosencher N, Kalebo P, Panfilov S, Eskilson C, Andersson M, Freij A. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboem-bolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost. 2003;1:2490-2496.
66. Eriksson BI, Agnelli G, Cohen AT, Dahl OE, Mouret P, Rosencher N, Eskilson C, Nylander I, Frison L, Ogren M. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost. 2003;89:288-296.
67. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003;349:1703-1712.
68. Fiessinger JN, Huisman MV, Davidson BL, Bounameaux H, Francis CW, Eriksson H, Lundstrom T, Berkowitz SD, Nystrom P, Thorsen M, Ginsberg JS. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA. 2005;293:681-689.
69. Schulman S, Wahlander K, Lundstrom T, Clason SB, Eriksson H. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med. 2003;349:1713-1721.
70. Albers GW, Diener HC, Frison L, Grind M, Nevinson M, Partridge S, Halperin JL, Horrow J, Olsson SB, Petersen P, Vahanian A. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005;293:690-698.
71. Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362:1691-1698.
72. Wallentin L, Wilcox RG, Weaver WD, Emanuelsson H, Goodvin A, Nystrom P, Bylock A. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet. 2003;362:789-797.
73. Kindmark A, Jawaid A, Harbron CG, et al. Genome-wide pharmaco-genetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Phar-macogenomics J. 2008;8:186-195.
74. Brandstetter H, Turk D, Hoeffken HW, Grosse D, Sturzebecher J, Martin PD, Edwards BF, Bode W. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA: a starting point for improving antithrombotics. J Mol Biol. 1992;226:1085-1099.
75. Hauel NH, Nar H, Priepke H, Ries U, Stassen JM, Wienen W. Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002;45:1757-1766.
76. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmaco-dynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15(Suppl 1):9S-16S.
77. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kalebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5:2178-2185.
78. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR. Dab-igatran etexilate versus enoxaparin for prevention of venous thromboem-bolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-956.
79. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ. Oral dabigatran versus enoxaparin for throm-boprophylaxis after primary total hip arthroplasty (RE-NOVATE I.I.*): a randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011; 105:721-729.
80. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thrombo-embolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1-9.
81. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.
82. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom JW, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
83. US Food and Drug Administration. FDA approves Pradaxa to prevent stroke in people with atrial fibrillation. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm230241.htm. 2010.